DFT, molecular docking, and ADME/Tox screening investigations of market‑available drugs against SARS‑CoV‑2 by Araújo, Joabe Lima et al.
Article J. Braz. Chem. Soc., Vol. 00, No. 00, 1-14, 2021©2021  Sociedade Brasileira de Química
https://dx.doi.org/10.21577/0103-5053.20210061
*e-mail: joabearaujobiotec@gmail.com; stanislav.stoyanov@canada.ca
DFT, Molecular Docking, and ADME/Tox Screening Investigations of 
Market‑Available Drugs against SARS‑CoV‑2
Joabe L. Araújo, *,a,b,c Lucas A. de Sousa,d Alice O. Sousa, b Ruan S. Bastos,b,c,e 
Gardênia T. Santos,f Mateus R. Lage,d,g Stanislav R. Stoyanov,*,h Ionara N. G. Passos,b 
Ricardo B. de Azevedoa and Jefferson A. Rochab,c
aPrograma de Pós-Graduação em Nanociência e Nanobiotecnologia,  
Departamento de Genética e Morfologia, Universidade de Brasília, 70910-900 Brasília-DF, Brazil
 bGrupo de Pesquisa em Ciências Naturais e Biotecnologia, Departamento de Ciências Naturais/Química, 
Universidade Federal do Maranhão, 65940-000 Grajaú-MA, Brazil
cGrupo de Pesquisa em Química Medicinal e Biotecnologia, Departamento de Ciências Naturais/Química, 
Universidade Federal do Maranhão, 65550-000 São Bernardo-MA, Brazil
dPrograma de Pós-Graduação em Ciência dos Materiais, Centro de Ciências Sociais, Saúde e Tecnologia, 
Universidade Federal do Maranhão, 65900-410 Imperatriz-MA, Brazil 
ePrograma de Pós-Graduação em Química Medicinal e Modelagem Molecular, Departamento de Química, 
Universidade Federal do Pará, 66075-110 Belém-PA, Brazil
fCoordenação do Curso de Enfermagem, Universidade Estadual do Maranhão, 65690-000 Colinas-MA, Brazil
gCoordenação do Curso de Ciência e Tecnologia, Universidade Federal do Maranhão,  
65800-000 Balsas-MA, Brazil
hNatural Resources Canada, CanmetENERGY Devon, 1 Oil Patch Drive, Devon, Alberta T9G 1A8 Canada
A series of drugs was investigated to determine structural, electronic and pharmacological 
properties, as well as the molecular affinity for the main protease of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). The drugs were submitted to density functional theory 
calculations to optimize structures and predict binding preferences. The optimized geometries were 
used in molecular docking simulations. In the docking study, the receiver was considered rigid and 
the drugs flexible. The Lamarckian genetic algorithm with global search and Pseudo-Solis and 
Wets with local search were adopted for docking. Absorption, distribution, metabolism, excretion 
and toxicological properties were obtained from the Pre-ADMET online server. In this series, the 
antiviral atazanavir showed the potential to inhibit the main protease of SARS-CoV-2, based on 
the free binding energy, inhibition constant, binding interactions and its favorable pharmacological 
properties. Therefore, we recommend carrying out further studies with in vitro tests and subsequent 
clinical tests to analyze its effectiveness in the treatment of SARS-CoV-2.
Keywords: drug repurposing, COVID-19, SARS-CoV-2, molecular docking, density functional 
theory (DFT)
Introduction
An outbreak of hospitalizations due to a possible 
pneumonia in December 2019 in the city of Wuhan, China 
is considered to mark the onset of the current coronavirus 
pandemic.1 On February 11, 2020, the World Health 
Organization (WHO) officially reported that the disease, 
known as COVID-19 (coronavirus disease 2019), was 
caused by a new virus, classified as severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus 
Study Group of the International Committee on Taxonomy 
of Viruses.2,3 The symptoms of COVID-19 have been 
reported to include a range of clinical and radiological 
characteristics, in addition to pneumonia.4
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The SARS-CoV-2 is a positive, non-segmented 
ribonucleic acid (RNA) β-coronavirus (subgenus 
sarbecovirus, subfamily Orthocoronavirinae).5 It is one of 
the seven coronaviruses that affects humans. Four of these, 
the α-coronaviruses HCoV-229E and HCoV-NL63 as well 
as the β-coronaviruses HCoV-HKU1 and HCoV-OC43 have 
low pathogenicity and cause mild respiratory symptoms 
in humans.1,5 The other two β-coronaviruses, severe 
acute respiratory syndrome coronavirus 1 (SARS-CoV-1) 
and Middle East respiratory syndrome coronavirus 
(MERS-CoV) cause severe and potentially fatal respiratory 
infections.6
As of March 20, 2021, SARS-CoV-2 infected 
approximately 122,445,668 people worldwide, resulting 
in a total of 2,703,547 deaths.7 Deeply concerned by the 
alarming levels of spread and severity, the WHO made 
the assessment that COVID-19 can be characterized as a 
pandemic.8 Currently, there are some treatment alternatives 
available for severe cases of SARS-CoV-2, such as the 
use of remdesivir, which was promoted by the Canadian 
government agency on July 27, 2020, as well as in other 
countries.9 The response of the research community has 
been vigorous, with numerous research projects and clinical 
trials being launched or planned, mainly in the countries 
most affected by COVID-19.10
Drug development is a costly and time-consuming 
process, where most of the new drug candidates are rejected 
due to the strict safety criteria required by regulatory 
agencies.10,11 Drug repurposing is an effective and quick 
drug development strategy for finding new inhibitory 
agents for infectious diseases.12 The repurposing of market-
available drugs to treat new or rare diseases is becoming 
increasingly attractive because it involves the use of 
de-risked compounds, with decreased costs and shorter 
timelines for development.13 Both computational data-
driven and experimental approaches have been employed 
for the identification of repurposable drug candidates.12 
Molecular docking is a structure-based computational 
strategy for predicting the complementarity between a 
drug ligand and a therapeutic target.14 Pharmocological 
analysis of electronic health databases, in combination 
with other strategies, such as molecular docking, density 
functional theory (DFT) study, predictions by Pre-
ADMET and experimental studies, is also effective for 
drug repurposing.15,16 Using computational screening, it is 
possible to predict drug’s activity for other pathogens, since 
several drugs have an inhibitory effect and action against 
various protease pathways present in viruses.17
Computational strategies based on molecular 
docking, density functional theory (DFT) and electronic 
databases have been employed to study and screen the 
pharmacological activity of antiviral drugs against key 
enzymes of SARS-CoV-2.1,2,18-21 In these studies, DFT 
provided fundamental insights based on the frontier orbital 
energies and spatial distributions as well as optimized 
geometries.2,18 This method has helped scientists to assess 
the stability of drugs and to compute structural, electronic 
and thermodynamic properties.22 These properties have 
been successfully used to better understand the behavior of 
drugs in biological systems.23,24 Frontier molecular orbital 
energies have been correlated with the calculated and 
experimentally determined properties of organic molecules 
screened as drug candidates.25
Molecular docking is widely used to perform virtual 
screening of organic, inorganic, natural, and synthetic 
compounds, and to propose and explore structural behavior 
of a ligand when it binds to a protein target.26,27 In the 
search for new inhibitory agents for the main pathogenic 
enzymes, molecular docking has been employed to predict 
the binding affinity of drugs to a receptor and to elucidate 
the active site.28,29
Pharmacological databases such as Pre-ADMET 
have been employed to complement drug repurposing 
studies by elucidating the pharmacological properties of 
absorption, distribution, metabolism, excretion, and toxicity 
(ADMET).30 The Pre-ADMET server provides results close 
to tests performed in laboratories, in addition to simulating 
Ames tests to obtain toxicological results of mutagenicity 
and carcinogenicity in mice and rats.31
This study aims to screen a series of market-available 
drug for repurposing to treat the new disease caused by 
SARS-CoV-2 by using three complementary computational 
methods. The series includes the anti-influenza and anti-
human immunodeficiency virus drugs approved by the 
Brazilian Health Regulatory Agency (ANVISA), Brazil. 
Moreover, the main protease inhibitor (Mpro) darunavir 
has been included as a control. The screening is conducted 
based on structural, electronic, and thermodynamic 
properties of the drugs under investigation both in 
vacuum and in the docking site of the main protease of 
SARS-CoV-2. Moreover, pharmacological database 
information is collected and used to identify the lead 
antiviral drug for further testing towards repurposing for 




The chemical  structures of the anti-human 
immunodeficiency virus drug atazanavir, antimalarial 
Araújo et al. 3Vol. 00, No. 00, 2021
chloroquine, and anti-influenza drugs rimantadine, 
amantadine, zanamivir, oseltamivir and the drug darunavir 
(for use as a control in the molecular docking studies) 
were prepared using the Chemcraft software32 in the 
Cartesian coordinate input file format needed for the 
subsequent calculations.33 The geometry of each compound 
was optimized in vacuum using DFT functional Becke, 
3-parameter, Lee-Yang-Parr (B3LYP)34-36 and the triple 
zeta 6-311++G(d,p) basis set37,38 as implemented in the 
Gaussian16 software suite.39 Each molecular geometry 
obtained was confirmed to be a true minimum in the potential 
energy surface by vibrational frequency calculations.40 The 
structural and electronic properties obtained from the 
calculations were analyzed, and the optimized geometries 
were used as input for the molecular docking simulations 
and for the development of the ADMET study.
Molecular docking simulation
The main protease (Mpro or 3CLpro) of SARS-CoV-2 
was obtained from the Protein Data Bank (PDB) database, 
with the identification code 6Y2E, where this free 
structure will allow analysis if the Glu288-Asp289-Glu290 
region is attractive for the series of drugs in this 
study. The SARS-CoV-2 Mpro was prepared using the 
CHIMERA  v.13.1 software41 by suppressing water 
molecules, ions and other residues present in the protein 
structure. This preparation was conducted to make the 
molecular affinity tests feasible, as presented in the protocol 
by Pettersen et al.41 and Araújo et al.42 The main protease of 
SARS-CoV-2 is selected as it is responsible for mediating 
viral replication and transcription, and its inhibition could 
prevent the development of the pathogen.43,44
Molecular docking was performed using the AutoDock 
Tools (ADT) version 1.5.6.45 The receptor was considered 
rigid and all ligands were treated as being flexible. 
Hydrogen was added to the partial charges of Gasteiger and 
was calculated. Non-polar hydrogen atoms were added to 
the protease and ligands. Then, a cubic box of 60 × 60 × 60 
grid points was created, with a grid resolution of 0.357 Å 
for the entire target protease (SARS-CoV-2 Mpro). The 
coordinates of the amino acid glutamato-290, X = -13.109, 
Y = -20.602 and Z = 24.681 were defined as the center 
of molecular affinity by GASS-WEB,46 a web server for 
identifying enzyme active sites based on genetic algorithms 
that has an average accuracy of 99%.47 The Lamarckian 
Genetic Algorithm with global search and pseudo-Solis 
and Wets with local search were adopted for molecular 
docking. The remaining parameters were adopted from the 
method of Ramos et al.48 For the docking of each drug, 100 
independent runs were carried out. The molecular affinity 
analysis criterion is based on the binding free energy, 
inhibition constant and hydrogen bonding interactions.49
ADME/Tox study
Pharmaceutical properties of ADMET were obtained 
using the Pre-ADMET50 online server, available at no 
cost for academic purposes.30 Parameters were obtained 
for the human intestinal absorption potential (HIA), drug 
absorption capacity (PCaco2) through cell penetration, skin 
permeability (Pskin), potential to cross the blood-brain 
barrier and reaction with P-glycoprotein. Drug metabolism 
was analyzed based on the efficiency of inhibition with the 
subfamilies CYP450. The toxicity parameters were obtained 
in accordance with the toxicological evaluation in relation 




The geometries of the series of antiviral drugs under 
investigation were optimized using DFT with Gaussian16 
software (Figure 1) and confirmed using vibrational 
frequency analysis.51,52 The geometry optimization results 
were used as input in the molecular docking studies and 
analyzed to obtain the electronic structure and reactivity 
parameters.53,54
The spatial distributions of the highest occupied 
molecular orbital (HOMO) and lowest unoccupied 
molecular orbital (LUMO) for each antiviral drug 
are presented in Figure 2.55 The HOMO and LUMO 
localizations describe the electron-donating and accepting 
moieties, respectively.
The DFT calculations provide parameters describing 
reactivity preferences, such as the HOMO and LUMO 
energies and the HOMO-LUMO energy gap as well as 
chemical potential (µ), defined as µ = -(ELUMO + EHOMO)/2, 
hardness (η), defined as η = (ELUMO - EHOMO)/2, softness (s), 
defined as s = 1/η and global electrophilicity (ω), defined 
as ω = µ2/2η.56,57 The electrophilicity measures the energy 
stabilization, defined as the ability of an electrophilic 
molecule to acquire an additional electron, and the 
system’s resistance to an electron charge exchange with 
the medium.58
Table 1 lists the calculated parameters of the series 
of antiviral drugs. The HOMO and LUMO energies 
are related to the propensity of the molecules to donate 
(ionization potential) and accept electrons (electron 
affinity), respectively. The HOMO-LUMO energy gap 
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Figure 1. Optimized geometries of (a) atazanavir, (b) rimantadine, (c) chloroquine, (d) amantadine, (e) zanamivir, and (f) oseltamivir, in structural 
representations prepared with Chemcraft software.32
Figure 2. Atazanavir (a), rimantadine (b), chloroquine (c), amantadine (d), zanamivir (e), and oseltamivir (f). The red and blue colors correspond to the 
positive and negative phases, respectively.
Table 1. Energy values of molecular reactivity descriptors
Property Atazanavir Rimantadine Chloroquine Amantadine Zanamivir Oseltamivir
EHOMO / eV -5.92 -6.40 -5.92 -6.65 -6.88 -6.51
ELUMO / eV -1.45 -0.45 -1.55 -0.33 -1.91 -1.50
EHOMO-LUMO / eV 4.47 5.95 4.37 6.32 4.97 5.01
µ / eV -3.68 -3.43 -3.73 -3.49 -4.40 -4.01
η / eV 2.24 2.98 2.18 3.16 2.49 2.51
s / eV 0.45 0.34 0.46 0.32 0.40 0.40
ω / eV 3.03 1.97 3.19 1.93 3.89 3.20
EHOMO: energy of the highest occupied molecular orbital; ELUMO: energy from the lowest unoccupied molecular orbital; EHOMO-LUMO: energy gap; µ: chemical 
potential; η: hardness; s: softness; ω: global electrophilicity.
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describes the hardness of the molecules, in terms of the 
Hard and Soft Acids and Bases theory of Pearson59,60 for the 
prediction of chemical reactivity in the context of DFT.61,62 
The negative values of the chemical potential indicate that 
the drug compounds are stable. Atazanazir and chloroquine 
have the highest HOMO energies (ionization potentials) 
as well as the lowest energy gaps and hardness values. 
The electrophilicity of zanamavir is the highest, followed 
by that of oseltamivir, chloroquine, and atazanavir. This 
order (Table 1) is correlated with the number of hydrogen 
bond donor sites as expressed by the number of H atoms 
of hydroxyl and amine groups (Figure 1). 
The electrostatic potentials mapped on the electron 
density surface (Figure 3) visualize the molecular regions 
with enhanced preference for electrostatic interactions, 
such as hydrogen bonding, which are prevalent in the 
binding between drugs and receptors.63-65 The red and 
blue regions presented in the electrostatic potential of 
atazanavir, zanamavir and oseltamivir highlight the regions 
or functional groups with nucleophilic and electrophilic 
interaction preferences, respectively.58,65 Regions that showed 
nucleophilic (hydrogen bond acceptor) character were 
noted at the carbonyl groups and pyridinic N atoms. The 
electrophilic H atoms of amine and hydroxyl groups (best 
seen in Figure 1) are hydrogen bond donors with substantial 
contributions to docking. Rimantadine and amantadine 
featured only one hydrogen bond acceptor site (red color) 
at the amine N atom. Chloroquine had several hydrogen 
bonding sites with low absolute charges. These results are 
important for studies of drug-protein interactions.63
Molecular docking simulation
Starting from the optimized geometries of the drugs 
using DFT and X-ray data of SARS-CoV-2 Mpro, molecular 
docking aims to find the best orientation for binding the drug 
to the target protease. This approach allows characterization 
and improved understanding of the bonding interactions 
at the target binding site.19 The binding free energies, 
inhibition constants and hydrogen bonding interaction 
results obtained from 100 independent docking simulations 
are presented in Table 2. The binding free energies are in 
the range from -5.25 to -6.47 kcal mol-1, representative of 
the docking of other antiviral drugs on the main proteases 
of coronaviruses.2,19,20,66 The standard error of AutoDock 
in binding free energies is estimated at 0.06 kcal mol-1, 
Figure 3. Electrostatic potential mapped on the electron density isosurface of (a) atazanavir, (b) rimantadine, (c) chloroquine, (d) amantadine, (e) zanamivir, 
and (f) oseltanavir.
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which is within the experimental error.67 Thus, obtaining 
the binding energy (ΔG) will allow to know which drugs 
express cytotoxic activity in vitro against the Mpro protein, 
since the molecular affinity indicates that the protein will 
bind to the drug, where the pharmacological properties of 
the drug will act on that target protein.
The results clearly indicate that atazanavir has the 
highest molecular affinity for the main SARS-CoV-2 
protease, with a free binding energy of -6.47 kcal mol-1, 
followed by rimantadine, chloroquine, amantadine, 
zamanavir, and oseltamivir. The inhibition constants 
increase in the same order as the binding free energies. 
Among the series of antiviral drugs investigated, atazanavir, 
rimantadine, chloroquine and amantadine are the most 
promising for binding to the SARS-CoV-2 Mpro because of 
the substantially higher affinity and stronger inhibition of 
the protease.42,68 The antiviral drugs atazanavir, zamanavir, 
and oseltamivir which contain more hydrogen bond donor 
and acceptor sites (Figure 3), have fewer conformations in 
the first cluster and tend to interact with more of the protease 
amino acids. Atazanavir effectively docks on the protease 
active center in a single conformation, whereas zanamavir 
docks in 11 conformations, followed by oseltamivir that 
docks in 38 conformations and the control darunavir that 
docks in 3 conformations (Table 2). Each of these four 
antiviral drugs interacts with several amino acids through 
hydrogen bonds, including Glu288, whereas the remaining 
antivirals interact only with Glu288.
The binding free energy calculations conducted using 
molecular docking are based on force fields that enable 
the exploration of wide regions of conformational space.69 
Ligand-protein interactions are defined by a combination 
of empirical and semi-empirical force field parameters.70 
It is important to note that the AutoDock calculations 
consider the desolvation of polar and nonpolar groups using 
empirical approaches.69
Figures 4, 5, 6 and S1 (Supplementary Information 
(SI) section) present the molecular docking interaction 
surfaces and detailed representations of the network of 
hydrogen bonding interactions of each drug with the main 
protease affinity center. The interactions between atazanavir 
and the target protease (Figure 4a) include 4 bridging 
hydrogen bonds to the amino acid residues Lys5 (lysine), 
Lys137, Glu290 (glutamic) and Glu288. The latter residue 
can be seen in all hydrogen bonding interactions of the 
generated complexes, as shown in Figures 4, 5, 6 and S1. 
Therefore, the amino acid residue Glu288 was identified 
as a potentially key site to inhibit the SARS-CoV-2 Mpro 
by allowing the antivirals to react and block the active 
region.71,72
The rimantadine presented the second best result 
of molecular affinity, with a binding free energy of 
-6.13 kcal mol-1 and an inhibition constant of 31.98 µM 
(Table 2). These results highlight the strong docking 
of the drug on the active site of the protease Mpro of 
SARS-CoV-2,72 where the most intense interaction of 
the complex occurs with the amino acid residue Glu288, 
which forms a 2.46 Å long hydrogen bridge between the 
rimantadine O and amino acid N (Figure 4b). In the amino 
acid residues Arg4 (arginine), Lys5, Leu282 (leucine), 
Phe291 (phenylalanine), Phe3, Ser284 (serine) and Trp207 
(tryptophan) for rimantadine, we observed substantial 
hydrophobic interactions at the edges of the protease active 
site, in addition to the hydrogen bonding bridge (Figure 4b).
Chloroquine and amantadine (Figure 5) are comparable 
in docking effectiveness with the Mpro protease of 
SARS-CoV-2, based on the binding free energy and 
inhibition constant (Table 2). Chloroquine is docked via 
a 2.55 Å hydrogen bond with Glu288 and hydrophobic 
interactions with the amino acid residues Asp289, Glu290, 
Leu282, Lys5, Leu286, Leu287, Phe3, Phe291, Ser284 and 
Trp207. The amantadine/Mpro complex has a binding free 










Interacting amino acids through hydrogen bonds
Atazanavir/Mpro -6.47 18.2 100 1 Lys5, Lys137, Glu290, Glu288
Rimantadine/Mpro -6.13 31.98 100 61 Glu288
Chloroquine/Mpro -5.59 79.37 100 61 Glu288
Amantadine/Mpro -5.58 80.98 100 100 Glu288
Zanamivir/Mpro -5.3 129.35 100 11 Asp289, Asp197, Glu288, Lys5, Lys137, Thr199
Oseltamivir/Mpro -5.25 142.87 100 38 Lys5, Lys137, Glu288, Asp289
Control
Darunavir/Mpro -5.71 65.39 100 3 Glu288, Leu287, Lys5
Complex: drug and protein; ΔGbind: Gibbs free energy; Ki: inhibition constant; Lys: lysine; Glu: glutamic acid; Asp: aspartic acid; Thr: treonina.
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Figure 4. Molecular docking: (a) molecular interaction between atazanavir and protease Mpro; (b) molecular interaction between rimantadine and protease 
Mpro. The protease Mpro surface color is mapped from red to blue to denote the most hydrophobic and hydrophilic regions, respectively.
Figure 5. Molecular docking: (a) molecular interaction between chloroquine and protease Mpro; (b) molecular interaction between the amantadine and 
protease Mpro. The protease Mpro surface color is mapped from red to blue to denote the most hydrophobic and hydrophilic regions, respectively.
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energy of -5.58 kcal mol-1 and an inhibition constant of 
80.98 µM (Table 2). This complex also forms a hydrogen 
bonding bridge to the amino acid residue Glu288 with 
a N…O distance of 2.51 Å and hydrophobic interactions 
with the amino acid residues Lys5, Leu282, Phe291, Phe3, 
Ser284 and Trp207, which interact at the edges of the 
SARS-CoV-2 Mpro active site (Figure 5).
Zanamivir was also promising when binding 
SARS-CoV-2 Mpro, with a binding free energy of 
-5.3 kcal mol-1 and an inhibition constant of 129.35 µM. 
The docking of zanamivir was stabilized through the 
formation of six hydrogen bonding bridges with the amino 
acid residues Asp289, Asp197, Glu288, Lys5, Lys137, 
and Thr199 (Figure 6). We observed once again that a 
hydrogen bond is formed at the amino acid residue Glu288, 
demonstrating that this site is an attractive site in molecular 
interaction studies for the SARS-CoV-2 Mpro.71 In the 
molecular interaction between the protease and oseltamivir, 
there were 4 hydrogen bridges to the amino acid residues 
Lys5, Lys137, Glu288 and Asp289 (Figure 6), yielding a 
binding free energy of -5.25 kcal mol-1 and an inhibition 
constant of 142.87 µM (Table 2).
Thus, it is already known that the residue regions at the 
N terminal (also known as the N finger) interact with two 
terminal domains of protomers A and B, this interaction 
has shown promise for dimerization.72 Thus, with these 
results we show that the Glu288-Asp289-Glu290 region 
within the extra domain are essential for inhibition of 
SARS-CoV-2, as also pointed out in studies by He et al.72 
and Vijayakumar et al.71
ADME/Tox study
The results of the absorption (Table 3), distribution 
(Table 4), metabolism (Table 5) and toxicity parameters 
(Table 6), predicted by Pre-ADMET were calculated 
and listed.30 The best results with respect to the human 
intestinal absorption potential (HIA) were amantadine 
and rimantadine, both with 100% absorption. The others 
also have high HIA percentages (85% or higher), with 
the exception of zanamivir, suggesting that they are well 
absorbed (Table 3).73
The permeability of Caco-2 cells (PCaco-2) is an important 
effectiveness evaluation factor for drugs pertaining to 
transport and absorption. Based on this, it is possible 
to predict how the drug behaves and moves from the 
intestine into the patient’s bloodstream.74,75 The values of 
PCaco-2 show average permeability for all drugs analyzed, 
with results from 14.12 to 56.61 nm s-1. We observed that 
the drugs atazanavir, amantadine and rimantadine have 
Figure 6. Molecular docking: (a) molecular interaction between zanamivir and protease Mpro; (b) molecular interaction between oseltamivir and protease 
Mpro. The protease surface color is mapped from red to blue to denote the most hydrophobic and hydrophilic regions, respectively.
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similar permeability values, while chloroquine stands out 
with the best permeability. According to Yazdanian et al.76 
permeability values between 4 and 70 nm s-1 are considered 
average. These below 4 nm s-1 are low and those in the 
70-100 nm s-1 range indicate high permeability.77 Skin 
permeability (Pskin) is important to determining whether the 
drug can be applied through transdermal administration.30 
All drugs studied showed negative values, indicating that 
these drugs are not lipophilic, cannot be absorbed by human 
skin, and must be administered orally.78
The distribution characteristics of the drugs were 
evaluated by binding to plasma protein (PPB), interaction 
with P-glycoprotein and through the brain-blood 
participation coefficient (Cbrain/Cblood) (Table 4). The 
drugs amantadine, atazanavir and chloroquine exhibited 
high values of 100, 86.56 and 92.53%, respectively, 
demonstrating a high potential to reach the bloodstream. 
Oseltamivir, rimantadine and zanamivir are classified as 
weakly-binding.
The penetration of the blood-brain barrier, reflected in 
the Cbrain/Cblood values, depends on the polarity of the antiviral 
compound. The barrier penetration directly affects the drug 
circulation in the central nervous system, as a rupture of this 
barrier is the main cause of degenerative diseases.79,80 The 
drugs amantidine, atazanavir, oseltanavir and zanamivir 
have Cbrain/Cblood values of 1.030, 0.285, 0.123 and 0.816, 
respectively, classified as average absorption, according to 
Ma et al.80 Chloroquine and rimantadine, with Cbrain/Cblood 
values of 7.734 and 2.015, respectively, indicated a greater 
potential for breaking the blood-brain barrier. Atazanavir 
was the only drug in this study that inhibited the action of 
the P-glycoprotein that is responsible for increasing cell 
resistance in new drugs and transporting various structures 
for adenosine triphosphate (ATP) binding.81,82
Cytochrome P450 (CYP450) is an important family of 
monooxygenases that is involved in drug metabolism. Thus, 
drugs must exhibit a substrate, inducer or inhibitor activity 
to the enzymes that integrate with CYP450 according to 
their specificity. When CYP450 inducers are included, a 
reduction in the effectiveness of the drug can be observed. 
On the other hand, the consequences of inhibiting CYP450 
include increased toxicity of the drug affected by the 
interaction, or reduced effectiveness, when the drug is a 
prodrug and depends on the activity of CYP450 enzymes 
to be activated.83,84 Thus, it is expected to obtain inhibiting 
activity in that CYP2C19, CYP2C9, CYP2D6 and CYP3A4 
enzymes and substrates in CYP2D6 and CYP3A4 (Table 5). 
Amantadine and rimantadine showed negative results for 
the CYP3A4 substrate. Atazanavir showed negative results 
Table 3. Absorption characteristics of antiviral agents
Drug name
Absorption characteristics
HIA / % PCaco-2 / (nm s-1) Pskin
Amantadine 100.00 21.32 -2.790
Atazanavir 88.54 21.20 -2.108
Chloroquine 98.06 56.61 -2.535
Oseltamivir 87.16 14.12 -3.349
Rimantadine 100.0 21.72 -2.747
Zanamivir 4.065 19.16 -5.137
HIA: human intestinal absorption potential; PCaco-2: permeability of Caco-2 
cells; Pskin: skin permeability.
Table 4. Distribution characteristics of antiviral agents
Drug name
Distribution characteristic
PPB / % Cbrain/Cblood
P-Glycoprotein 
inhibition
Amantadine 100.0 1.030 non
Atazanavir 86.56 0.285 inhibitor
Chloroquine 92.53 7.734 non
Oseltamivir 37.83 0.123 non
Rimantadine 4.988 2.015 non
Zanamivir 0.000 0.816 non
PPB: plasma proteins binding; Cbrain/Cblood: brain-blood participation 
coefficient.















Amantadine inhibitor inhibitor inhibitor weakly inhibitor non
Atazanavir inhibitor inhibitor non non inhibitor substrate
Chloroquine non non inhibitor substrate non substrate
Oseltamivir non non inhibitor substrate non weakly
Rimantadine inhibitor inhibitor inhibitor substrate inhibitor non
Zanamivir non non non non non weakly
CYP: cytochrome.
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for the CYP2D6 substrate. Chloroquine and oseltamivir 
inhibited CYP2D6, with oseltamivir having weak activity 
on the CYP3A4 substrate. Zanamivir was the least active 
in the CYP450 family, only showing weak activity towards 
the CYP3A4 substrate. The results indicated that the drugs 
amantadine, atazanavir and rimantadine were the most 
promising candidates based on the effective interactions 
with the CYP450 enzymes.49
In Table 6, the mutagenicity results (Ames test) and 
the carcinogenic properties in mice and rats are listed. 
Among the 6 drugs evaluated, amantadine, chloroquine 
and rimantadine showed mutagenicity based on the Ames 
tests. The Ames test is accepted by the scientific community 
as a way of evaluating the mutagenicity of compounds by 
using different strains of salmonella.85 Only amantadine 
showed carcinogenic activity in mice. For rats, amantadine, 
chloroquine, and rimantadine showed positive results for 
carcinogenicity.
Table S1 found in the SI section lists the side effects 
of each drug analyzed in this study.86 It can be seen that 
each drug has a number of serious side effects that must 
be reported immediately to the doctor and require the 
immediate suspension of the treatment.
Discussion
The results indicated that all seven drugs dock 
effectively on the main Mpro SARS-CoV-2 protease, based 
on the negative binding free energies, low inhibition 
constants and extensive hydrogen bonding and hydrophobic 
interactions presented in Table 2 and Figures 4, 5, 6 and 
S1 found in SI section. Among these, the best candidate 
based on docking was atazanavir, followed by rimantadine, 
the equally-performing chloroquine and amantadine, and 
the last on the binding free energy list, zanamavir and 
oseltamivir. This order is in partial agreement with the 
EHOMO decrease order (Table 1) of atazanavir comparable 
to chloroquine, followed by rimantadine, oseltamivir, 
amantadine and zanamavir, indicating that the docking 
strength correlates with the electron donating or ionization 
potential of the drug. The HOMO and LUMO spatial 
distributions are localized on the hydrogen bond acceptor 
and donor moieties, respectively (Figure 2). Moreover, the 
four drugs with the best docking affinity (lowest binding 
free energies and inhibition constants) have substantially 
higher chemical potential, indicative of increased reactivity, 
than zanamivir and oseltamivir. The hydrogen bond donor 
and acceptor preferences of the drug molecules highlighted 
in the electrostatic potential maps (Figure 3) correlate 
with the hydrogen bonding networks from the docking 
simulations (Figures 4, 5 and 6).
The binding free energies of atazanavir and 
rimantadine were close to those calculated for the 
bis-(3,5,5-trimethylhexyl) phthalate compounds, myristicin, 
eugenol and 6-shogaol in studies carried out by Tallei et al.87 
for the same target protease (Mpro) by molecular docking. 
Moreover, these two drugs also performed better compared 
to the main inhibitor (darunavir) of this protease, used 
as a control in this study, with a binding free energy of 
-5.71  kcal mol-1 (Table 2). Atazanavir and rimantadine 
have a high capacity to bind to the main protease, which 
is responsible for catalyzing the processing of viral 
polyprotein and, therefore, inhibit viral infection by 
SAR-CoV-2 in humans.87
In addition to having the highest docking affinity with 
a single conformation, atazanavir, has negative results 
for carcinogenicity in Ames tests by Pre-ADMET.85 
Moreover, atazanavir is the only drug in this study to 
inhibit P-glycoprotein, responsible for preventing the 
action of new drugs in the body, so its inhibition is 
essential for the distribution of the drug and transporting 
various structures for ATP binding.81 P-Glycoprotein is 
also located at the villus tip of enterocytes in the gut, thus, 
drugs with oral administration that inhibit the action of 
P-glycoprotein cross this physiological barrier effectively 
for the distribution of its pharmacological properties in the 
organism.88 Knowing that this drug is already available in 
the pharmaceutical market for the treatment of infections 
by the human immunodeficiency virus,89 human studies 
are advantageous because of the current need to discover 
a SARS-CoV-2 inhibitory agent by the drug repositioning 
method.
These findings demonstrate that both rimantadine and 
chloroquine are also potentially attractive for studies of 
the main SARS-CoV-2 protease,71 having strong hydrogen 
bonding interactions with the amino acid residue Glu288 
and high binding affinities, indicating that both interact 
strongly with the active site of the key pathogen protein. 
This molecular affinity indicates that the drugs express 






Amantadine mutagen positive positive
Atazanavir non-mutagen negative negative
Chloroquine mutagen negative positive
Oseltamivir non-mutagen negative negative
Rimantadine mutagen negative positive
Zanamivir non-mutagen negative negative
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cytotoxic activity against the Mpro protein. In a study by 
Li et al.90  it was shown that atazanavir and chloroquine 
has cytotoxic action inhibiting cell viability by 50% (IC50) 
at a concentration of 7.53 ± 0.31 and 7.16 ± 0.23 μM, 
respectively. These findings validate the computational 
prediction by molecular docking, where the drug showed 
molecular affinity to bind to the Mpro protein.
However, chloroquine has highly toxic and its use 
can lead to complications, for example, in patients with 
acute or cutaneous porphyria, the use of chloroquine can 
trigger an acute attack with fever and intense elevations 
of the aminotransferase, potentially leading to jaundice.91 
Chloroquine also shows positive results for carcinogenicity 
(Table 6), as in long treatments, it can stimulate cell 
damage, causing uncontrolled cell division by mitosis, 
potentially leading to malignant tumors.92 In addition, 
chloroquine may cause hypoglycemia, neuropsychiatric 
effects, drug interactions and idiosyncratic hypersensitivity 
reactions, thus further aggravating the treatment outcomes 
for patients affected by COVID-19, as reported in cases of 
treatment with chloroquine.93
Conclusions
A series of market-available drugs for the treatment of 
influenza infections caused by the human immunodeficiency 
virus and influenza were evaluated for repurposing to 
inhibit SARS-CoV-2 (Mpro) using DFT calculations, 
molecular docking simulations, and pharmacological 
database screening. The drugs were found to interact with 
the protease through hydrogen bonding and hydrophobic 
interactions, as revealed by docking and DFT studies. The 
binding affinity was correlated partially with the HOMO 
energies, indicating that electron donation from the drug 
to the protein is important. Pharmacological screening 
identified drugs with high absorption and favorable 
distribution, metabolic, and toxicological characteristics.
The results identified atazanavir as the drug with the 
highest docking affinity (-6.47 kcal mol-1) and the strongest 
inhibition of the main protease, as it formed numerous and 
strong hydrogen bonds. As well as its molecular affinity 
stood out in comparison to the main inhibitor of Mpro 
(darunavir) in the Glu288-Asp289-Glu290 region, which 
obtained a molecular affinity value of -5.71 kcal mol-1. It 
also has the best pharmacological potential, as evidenced 
by inhibition of the action of P-glycoprotein, responsible 
for increasing cell resistance in new drugs and transporting 
various structures for ATP binding. The toxicological data 
indicated that atazanavir was the only drug in the series that 
was negative for both carcinogenicity and mutagenicity. 
Based on this in silico screening, atazanavir was identified 
as a good candidate for in vitro testing and subsequent 
clinical testing for the treatment of SARS-CoV-2.
Supplementary Information
Supplementary information (the molecular interaction 
between darunavir and protease (Mpro), along with the color 
of the protein’s surface that is mapped from red to blue 
to denote the most hydrophobic and hydrophilic regions, 
respectively, are in Figure S1, and in Table S1 are the 
common and serious side effects of atazanavir, rimantadine, 
chloroquine, amantadine, zanamivir and oseltamivir) is 
available free of charge at http://jbcs.sbq.org.br as PDF file.
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